Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Moses R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	type 2 diabetes metformin repaglinide PrandiMet® fixed-dose combination Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/f258fc99a07a408ba0b23c9f089a972e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f258fc99a07a408ba0b23c9f089a972e
record_format	dspace
spelling	oai:doaj.org-article:f258fc99a07a408ba0b23c9f089a972e2021-12-02T06:04:13ZRepaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update1178-7007https://doaj.org/article/f258fc99a07a408ba0b23c9f089a972e2010-05-01T00:00:00Zhttps://www.dovepress.com/repaglinidemetformin-fixed-dose-combination-to-improve-glycemic-contro-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwide. Lifestyle advice plus metformin is commonly recommended initially to manage hyperglycemia and to minimize the risk of vascular complications. However, additional agents are required when glycemic targets cannot be achieved or maintained due to the progressive nature of the disease. Repaglinide/metformin fixed-dose combination (FDC) therapy (PrandiMet®; Novo Nordisk, Bagsværd, Denmark) has been approved for use in the USA. This FDC is a rational second-line therapy given the complementary mechanisms of action of the components. Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control.Keywords: type 2 diabetes, metformin, repaglinide, PrandiMet®, fixed-dose combinationMoses RDove Medical Pressarticletype 2 diabetesmetforminrepaglinidePrandiMet®fixed-dose combinationSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 145-154 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes metformin repaglinide PrandiMet® fixed-dose combination Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes metformin repaglinide PrandiMet® fixed-dose combination Specialties of internal medicine RC581-951 Moses R Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
description	Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwide. Lifestyle advice plus metformin is commonly recommended initially to manage hyperglycemia and to minimize the risk of vascular complications. However, additional agents are required when glycemic targets cannot be achieved or maintained due to the progressive nature of the disease. Repaglinide/metformin fixed-dose combination (FDC) therapy (PrandiMet®; Novo Nordisk, Bagsværd, Denmark) has been approved for use in the USA. This FDC is a rational second-line therapy given the complementary mechanisms of action of the components. Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control.Keywords: type 2 diabetes, metformin, repaglinide, PrandiMet®, fixed-dose combination
format	article
author	Moses R
author_facet	Moses R
author_sort	Moses R
title	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_short	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_full	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_fullStr	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_full_unstemmed	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_sort	repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/f258fc99a07a408ba0b23c9f089a972e
work_keys_str_mv	AT mosesr repaglinidemetforminfixeddosecombinationtoimproveglycemiccontrolinpatientswithtype2diabetesanupdate
_version_	1718400087329079296

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

Ejemplares similares